anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tomatoes contain a range of polyphenols that are of low bioavailability and reach the colon. Data from animal studies suggest that certain polyphenols are extensively metabolized by the gut microbiota which may impact bioactivity including TMA/TMAO production. It was previously shown that a polyphenol-rich cranberry extract attenuated diet-induced metabolic syndrome in mice in a gut microbiota-dependent manner. In another mouse study the polyphenol resveratrol attenuated TMAO-induced atherosclerosis by decreasing TMAO levels and increasing hepatic bile acid neosynthesis via gut microbiota remodelling. However, human studies on polyphenol effect on TMAO levels and the gut microbiome are sparse. In a recent study TMAO serum levels were reduced in healthy subjects upon supplementation with a grape pomace polyphenolic extract.

This clinical study will provide new insight into the effect of tomato extract on TMAO levels and the gut microbiota composition and thus potential new mechanisms responsible for the cardiovascular protective effects.
The invention discloses long-chain non-coding RNA for inhibiting CVB5 virus replication and application thereof, and relates to the technical field of biological medicine. The RNA is inter-gene long-chain non-coding RNA LINC1392; the nucleic acid sequence of LINC1392 is shown in SEQ ID NO. 1. The LINC1392 of the invention is positioned in cytoplasm and has basic expression characteristic depending on CVB5 virus infection dose. Experiments show that when the LINC1392 provided by the invention is knocked down, the replication level of CVB5 virus is obviously increased compared with that of a control group, namely the LINC1392 provided by the invention has the effect of inhibiting the replication of CVB5 virus. After the LINC1392 sequence provided by the invention is synthesized, the LINC1392 sequence can be used for further preparing medicines for preventing CVB5 virus infection and is used for preventing and treating hand-foot-mouth disease.
The present invention relates to a lip cosmetic composition having lip coating and long-lasting effects. More specifically, a fluorine-based derivative is contained, so lip placing properties are improved. A thin film screen is coated on the lip, so durability is improved. A hydrophobic silica component is contained, so the fluorine-based derivative is stabilized. The color of the lip is maintained, so a vivid lip makeup effect is provided. Since the fluorine-based derivative and the hydrophobic silica are contained, adsorption of the fluorine-based derivative is improved, and clean lip makeup can be maintained for a long time without staining or removal of the color on the lip. The lip cosmetic composition comprises 44.5 to 97.3 wt% of a fluorine-based derivative, 1 to 15 wt% of hydrophobic silica, 0.1 to 15 wt% of a film forming agent, 0.1 to 20 wt% of a resin, 1 to 5 wt% of vegetable oil, and 0.1 to 0.5 wt% of fragrances. The fluorine-based derivative is polyperfluoromethylisopropyl ether, and the hydrophobic silica is silica silylate.
An at-risk youth protection system is disclosed for securing and enabling authorized access to one or more life documents of youth. The system comprising a server including a database that stores life documents in accounts associated with a plurality of youth users of the system. The database further includes a user management system that controls authorization and security levels for system administrator users, case manager users, and youth users. The system administrator users have full access and editing privileges to all the accounts associated with the plurality of youth users. The case manager users have full access and editing privileges to only accounts associated with youth users to which they have been assigned. The youth users only have access privileges to their own accounts.
FIELD: biotechnology, immunology, pharmacy. SUBSTANCE: invention relates to vaccine against urogenital infections based on vaginal suppository. Invention involves suppositorium used for prophylaxis of infectious urogenital diseases, such as urinary way infections. Suppositorium comprises inactivated microorganisms of cultures from 8 to 14 strains of the following uropathogenic species: E. coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus morganii and Streptococcus faecalis isolated from human urine suffering with urinary ways infection and polyethylene glycol base of suppositorium. Invention relates to method for prophylaxis of urogenital diseases also. The advantage of invention involves the development of a device for vaccine delivery based on suppositorium using for prophylaxis of urogenital diseases. EFFECT: valuable medicinal properties of vaccine. 29 cl, 1 dwg
Coronary atherosclerosis is a leading cause of mortality and disability worldwide. Continuous efforts are needed to improve secondary prevention and understand the mechanism underlying disease progression. Based on primary prevention trials, a potential benefit of the Mediterranean diet after an acute coronary syndrome can be anticipated. The integrated microbiome-mediated/ immunologic and metabolic pathways by which the Mediterranean diet modifies cardiovascular risk remain mostly unknown. Intestinal and oral dysbiosis is involved in the pathogenesis of atherosclerosis and microbiome dynamics may account for some of the observed benefits of Mediterranean diet. The first objective of the trial is to evaluate the effects of a well-controlled Mediterranean diet intervention on atherosclerotic plaque vulnerability and coronary endothelial dysfunction after an episode of acute coronary syndrome. The second objective is to decipher the interplays among diet, microbiota, immunity and metabolism responsible for the observed effects. The investigators propose a randomized mechanistic clinical trial, using state-of-the-art efficacy read-outs. The multidisciplinary consortium includes highly experienced cardiologists, nutritionists and experts in translational research in immunology, microbiomics, genomics, proteomics, metabolomics and metagenomics. This study will provide valuable insights to identify potential microbiome therapeutic targets for coronary artery disease.
The invention discloses a composite liposome adjuvant and a preparation method thereof, wherein the encapsulation rate of the composite liposome adjuvant is 90.08%, the particle size is 110+/-20 nm, and the potential is-20.30+/-10.65 mV. The invention also discloses a foot-and-mouth disease subunit vaccine, which contains the composite liposome adjuvant and foot-and-mouth disease VLPs. The composite liposome adjuvant obtained by the test has good encapsulation efficiency and smaller nanometer particle size. And the preparation method of the composite liposome adjuvant is simple, easy to amplify and suitable for large-scale production and application. The composite liposome adjuvant prepared by the invention is used for preparing foot-and-mouth disease subunit vaccine to immunize healthy pigs; ELISA antibody titers and neutralizing antibody titers of the post-immunization experimental groups were higher than those of the commercial group. The composite liposome adjuvant prepared by the invention has better immune effect on foot-and-mouth disease subunit vaccine and better effect than the commercial adjuvant applied in the current market. Is suitable for large-scale commercial application in foot-and-mouth disease subunit vaccine.
PURPOSE:To obtain a 5-HT3 receptor antagonist useful for central diseases, vomiting, etc., containing a gamma-carboline derivative or a nontoxic acid addition salt or a hydrate thereof. CONSTITUTION:A 5-HT3 receptor antagonist containing a gamma-carboline derivative shown by formula I or a nontoxic acid addition salt (e.g. hygrochloride or hydrobromide) or a hydrate thereof. The compound shown by formula I is obtained by reacting a compound shown by formula II with a compound shown by formula III (X is halogen) and N-alkylating. The compound shown by formula I is effective for treating and preventing vomiting during use of anti-cancer drug such as especially cisplatin. A dose of the compound shown by formula I is usually 50mug to 10mg per adult per time and the compound is orally administered once-several times. Or the dose is 5mug to 10mg per adult per time and the compound is parenterally administered once to several times daily (preferably intravenously).
BACKGROUND: Few certainties exist regarding optimal management of Blood Pressure (BP) in the very first hours after an ischemic stroke and many questions remain still unanswered. Our work aimed to evaluate the role of BP and its trend as possible determinants of in-hospital mortality (primary outcome), discharge disabilities and hospitalization length (secondary outcomes) in ischemic stroke patients presented with Hypertensive Emergencies (HE).
METHODS: We retrospectively evaluated patients presented to Niguarda Hospital, Emergency Department (ED), from 2015 to 2017 with a neurological ischemic HE. BP at ED presentation (T0), its management in ED (T1) and its values at the stroke unit admission (T2) were evaluated.
RESULTS: 267 patients were included (0.13 % of all ED accesses and 17.9 % of all ischemic strokes). In the whole population, BP values were not associated with in-hospital mortality while T0 and T2 SBP result were associated to discharge disability and hospitalization length. In pre-specified subgroup analysis these associations were confirmed only in untreated subjects (not anti-hypertensive nor thrombolysis). In fact, no significant relationship can be found between BP values and any secondary outcome in thrombolysis and anti-hypertensive treated patients.
CONCLUSIONS: BP values and its management can not be related to in-hospital mortality in stroke patients, presented with HE, while they are associated to discharge disability and hospitalization length. In subgroup analysis, results were confirmed only in untreated (not anti-hypertensive therapies nor thrombolytic).
When randomly allocated to this arm, a conventional Foley-type catheter will be inserted during all the study period (4 weeks). At day 28 after inclusion, the patient will be called for a follow-up visit to remove the catheter.
Eravacycline was administered intravenously (IV) at a dose of 1.0 milligram per kilogram of body weight (mg/kg) every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days. Eravacycline treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
A wireless device, an app on a wireless device, and a method for automated diagnosis of radiographs is described. The app prompts a user to capture a photograph of a radiograph external to the mobile device with the mobile device's camera. The quality of the photograph is assessed and an error condition is reported if the quality is insufficient. A module displays on the mobile device display (1) a diagnosis that is assigned to the radiographs and (2) at least one similar radiograph. The diagnosis is assigned by subjecting the photograph to a deep learning model trained on a large corpus of labelled radiographs. The deep learning model can be resident on the mobile device or in a back end server. The app includes tools for enabling the user to select and navigate the input photograph and the similar radiograph by means of hand gestures on the display, and a tool for displaying medical knowledge associated with the diagnosis.
PURPOSE OF REVIEW: This review critically evaluates the current state of bladder-sparing options in muscle-invasive bladder cancer (MIBC) and provides an overview of future directions in the field.
RECENT FINDINGS: Bladder-sparing treatments have emerged as viable alternatives to radical cystectomy (RC) for selected patients with MIBC, especially in those who are unfit for RC or elect bladder preservation. Numerous studies have assessed the efficacy of trimodal therapy (TMT), with outcomes comparable to RC in a subgroup of well selected patients. Combining immunotherapy with conventional treatments in bladder-sparing approaches can yield promising outcomes. Current research is making significant progress in optimizing treatment protocols by exploring new combinations of systemic therapy agents, innovative drug delivery methods, and biomarker-based approaches. Furthermore, clinical markers of response are being tested to ensure adequate response assessment.
SUMMARY: Bladder preservation promise to offer a viable alternative to RC for selected patients with MIBC with the potential to improve patient quality of life. Careful patient selection and ongoing research are essential to optimize patient selection, response assessment, and salvage strategies. As evidence continues to evolve, the role of bladder preservation in MIBC is likely to expand, providing patients with more treatment options tailored to their needs and preferences.
All participants are candidates for IVF having PCOS or having PCO patterns in their ovaries who wish to undertake IVM for the potential advantages that it holds. All cycles are proceeded by oral contraceptive use for cycle scheduling purposes. Priming is done with oral letrozole with the addition of 25-75 IU daily starting after 2 days of letrozole. HCG is given when several follicle have diameters 8 mm or greater and no follicles have diameters greater than 13 mm. Oocyte retrieval is done approximately 38 hours later. A Steiner-Tan needle is used for oocyte retrieval in a manner that minimizes the amount of time that an oocyte is out of the ovary and not in a controlled laboratory environment. Oocytes are assessed for maturity for up to 48 hours post retrieval. If mature, oocytes are injected with sperm using ICSI. Embryos are grown to blastocysts and all blastocyst are vitrified. Warmed cryo-preserved blastocyst are transferred using routine IVF protocols during a subsequent cycle.
Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging T7 (7th thoracal vertebrae ) transverse process accompanied by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
ATF6 has been described as an endoplasmic reticulum (ER) stress-regulated transmembrane protein that activates the transcription of molecular chaperones in response to ER stress. Patients harboring mutations in ATF6 present with decreased retinal function and are diagnosed with achromatopsia. The investigator's research group has previously demonstrated that administration of glycerol phenylbutyrate (PBA), a fatty acid compound that facilitates protein folding, can lead to enhanced retinal function in mice that are homozygous for the ATF6 mutation. This study will investigate the effects of PBA administration in two patients who carry ATF6-/- mutations and a diagnosis of achromatopsia. Enrolled subjects will undergo a minimum of 3 clinic visits that consist of a complete ophthalmic examination (best-corrected visual acuity, intraocular pressure, anterior segment examination, slit lamp and binocular fundus examination), a visual functioning questionnaire, color vision tests, contrast sensitivity tests, retinal imaging (optical coherence tomography, short wavelength autofluorescence and near-infrared autofluorescence), a macular sensitivity test (Nidek microperimetry) and full-field electroretinogram (ffERG). A blood draw will be performed at each visit to test for any indications of adverse effects from drug use. Subjects will be instructed to take 3 doses of PBA per day, totaling to a dose of 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day).
PURPOSE: A lipid composition containing ceramide, stearic acid, oil tackifier, and selectively cholesterol is provided to ensure lip moisturizing and to recover lip skin barrier function. CONSTITUTION: A lipid composition for lip contains 10-80 weight% of ceramide, 10-80 weight% of stearic acid, and 3-80 weight% of oil tackifier as an active ingredient. The ceramide is a ceramide analogue. The lipid composition further contains cholesterol as an active ingredient. The weight ratio of ceramide, stearic acid, cholesterol, and oil tackifer is 1-4 : 1-4 : 1-2 : 1-4. A cosmetic composition contains 0.01-40 weight% of lipid composition.
Bronchial airways and lung parenchyma undergo both static and dynamic stretch in response to normal breathing as well as in the context of insults such as mechanical ventilation (MV) or in diseases such as asthma and chronic obstructive pulmonary disease (COPD) which lead to airway remodeling involving increased extracellular matrix (ECM) production. Here, the role of fibroblasts is critical, but the relationship between stretch- and fibroblast-induced ECM remodeling under these conditions is not well-explored. Piezo (PZ) channels play a role in mechanotransduction in many cell and organ systems, but their role in mechanical stretch-induced airway remodeling is not known. To explore this, we exposed human lung fibroblasts to 10% static stretch on a background of 5% oscillations for 48 h, with no static stretch considered controls. Collagen I, fibronectin, alpha-smooth muscle actin (α-SMA), and Piezo 1 (PZ1) expression was determined in the presence or absence of Yoda1 (PZ1 agonist) or GsMTx4 (PZ1 inhibitor). Collagen I, fibronectin, and α-SMA expression was increased by stretch and Yoda1, whereas pretreatment with GsMTx4 or knockdown of PZ1 by siRNA blunted this effect. Acute stretch in the presence and absence of Yoda1 demonstrated activation of the ERK pathway but not Smad. Measurement of [Ca2+]i responses to histamine showed significantly greater responses following stretch, effects that were blunted by knockdown of PZ1. Our findings identify an essential role for PZ1 in mechanical stretch-induced production of ECM mediated by ERK phosphorylation and Ca2+ influx in lung fibroblasts. Targeting PZ channels in fibroblasts may constitute a novel approach to ameliorate airway remodeling by decreasing ECM deposition.NEW & NOTEWORTHY The lung is an inherently mechanosensitive organ that can respond to mechanical forces in adaptive or maladaptive ways, including via remodeling resulting in increased fibrosis. We explored the mechanisms that link mechanical forces to remodeling using human lung fibroblasts. We found that mechanosensitive Piezo channels increase with stretch and mediate extracellular matrix formation and the fibroblast-to-myofibroblast transition that occurs with stretch. Our data highlight the importance of Piezo channels in lung mechanotransduction toward remodeling.
The universe of patients with coronary artery disease (CAD) has been increasing steadily worldwide. And associated intimately with certain cardiovascular risk factors such as dyslipidemia , decreased HDL-C , hypertension , diabetes mellitus and obesity. The quality of the fat in the diet influences the incidence of obesity and dyslipidemia. A high intake of saturated fat in different populations is associated with elevated serum cholesterol concentration and cardiovascular mortality. However, studies have shown that extra virgin coconut oil (Cocos nucifera L.) despite being characterized by its high content of saturated fat was not associated with obesity and dyslipidemia in populations that had their high consumption . And this is due to the high proportion of medium chain triglycerides , especially lauric acid in proportions ranging from 45-50 % , and the presence of factors antioxidants like vitamin E and polyphenols. Our hypothesis is that extra virgin coconut oil associated with a nutritional treatment has an effect on weight reduction and control of dyslipidemia contributes to control in secondary prevention in patients with coronary artery disease. All participants will be informed about the research and they must sign a consent form . Volunteers will be divided into two groups : a group receiving dietary treatment for 6 months and the other beyond the dietary treatment during the 6 months starts to receive supplementation with coconut oil extra virgin from 3 months, both groups evaluated monthly . At each visit , weight assessment , compliance with diet and blood pressure measurement is performed. In addition , the blood will also be collected for determination of glucose, insulin, total cholesterol, LDL-cholesterol , HDL-cholesterol, triglycerides , apolipoprotein A and B. The results will be analyzed by the statistical program.It is expected that the results obtained, the extra virgin coconut oil can be used as a coupled secondary prevention in patients with coronary artery disease.Our hypothesis is that extra virgin coconut oil associated with nutritional treatment has an effect on weight reduction and control of dyslipidemia contributes to control in secondary prevention in patients with coronary artery disease.
A bloodstream infection predicting system is proposed. The bloodstream infection predicting system includes a memory unit and a processor. The memory unit stores a plurality of historical medical data, a real-time data to be tested and a machine learning algorithm. The processor is configured to implement the above steps. The first data reading step is performed to read the historical medical data. The model training step is performed to train the historical medical data to generate a bloodstream infection predicting model. The second data reading step is performed to read the real-time data to be tested of a patient. The risk predicting step is performed to input the real-time data to be tested to the bloodstream infection predicting model to generate a bloodstream infection risk probability. The real-time data to be tested includes an intensive care unit (ICU) detecting data which is detected during a feature window period and a hematology feature data. Thus, the bloodstream infection predicting system of the present disclosure can predict the bloodstream infection risk probability after a specific time, and the medical treatment can be given immediately.
Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles. The starting dose for all Group 1 patients will be 600 mg BID. The first 2 patients with moderate hepatic impairment (Group 2) that enter Part II will receive a starting dose of 400 mg BID rucaparib; a lower dose of rucaparib may also be set based on PK results observed in Part I. If this initial starting dose is determined to be safe and tolerable as determined by real-time PK data and dose limiting toxicities (DLT) observed during the first 28 days of rucaparib, the starting dose of rucaparib may be increased in subsequent Group 2 patients. The starting dose for Group 2 patients may also be lowered, based on the patients' real time PK and emerging safety data. The Sponsor and key clinical research organization (CRO) staff will review available adverse event, laboratory, and PK data to determine the starting dose for subsequent Group 2 patients, as well as allowing intra-patient dose escalation of rucaparib after Cycle 1.Treatment with rucaparib will continue until progression of disease, unacceptable toxicity, death, loss to follow-up, withdrawal of consent, or other appropriate clinical reason for discontinuation.